TRANSCELL Oncologics

TRANSTOXBIO – An invitro cell based platform portfolio

A portfolio with human surrogate in vitro platforms as real time predictive solutions for preclinical research, development and testing

www.transtoxbio.com

About Transtoxbio

Transtoxbio is a product portfolio of Transcell Oncologics
Transcell Oncologics operates from India and the USA to address global needs

Transtoxbio offers human derived stem cell based primary configured platform systems that can be integrated into
Covid-19 drug discovery, development, exploratory toxicity testing

OUR PRODUCTS PORTFOLIO

- Ethically Immuned Sources to Harvest Cellular Component
- Cell Based Platforms Mimicking Human Milieu
- Considered as alternatives to animals; transformed cell lines
- Employed for invitro preclinical exploratory drug and cosmetics research, development

OUR SERVICES

- Exploratory preclinical in vitro research Services
- Specialty in vitro Toxicity Testing Services

For COVID-19
DRUG AND VACCINE PIPELINE TESTING
PRE-CLINICAL DEVELOPMENTAL

SPECIALTY CONTRACT RESEARCH SERVICE New

Transtoxbio supports invitro drug and vaccine discovery developmental exploratory preclinical testings on human surrogate cell based systems with predictive powers

PRECLINICAL TOXICITY IN VITRO EXPLORATORY SCREENING
ANTIGENS, ADJUVANTS, VACCINES, VEHICLES, DRUG CANDIDATES

HEMATOTOXICITY
PYROGENICITY
MUTAGENICITY
GENOTOXICITY
TUMOROGENICITY
DEVELOPMENTAL TOXICITY
TOXICOGENOMICS
TOXICOPROTEOMICS

CELL DISTRIBUTION APOPTOSIS NECROSIS STEM CELL CYTOTOXICITY LUNG CELL TOXICITY

OUR PORTFOLIO SYSTEMS - PHENOTYPICALLY RESPONSIVE CELL BASED PLATFORMS



TRANS-HSC

(CAT# TR-HSC)-Frozen



TRANS-MSC

(CAT# TR-MSC-50m)-Frozen

OUR PORTFOLIO PRODUCTS - HUMAN SURROGATE INVITRO SYSTEM

TRANS-HSC-CBCD34+

TRANS-HSC-CBCD34+ is an invitro (human cord blood) sourced primary progenitor cell based platform model composed of magnetically fractionated CD34+ cell aggregates system

Recommended

- ✓ As an invitro platform to screen toxicity of test candidates
- ✓ As an invitro platform to measure Hematopoiesis

Ready to use; No culturing procedure involved to apply with customized configuration

- **Catalogue Number :** TRANS-HSC-CBCD34+
- **Source:** Human Umbilical Cord blood

HEMATOTOXICITY – PYROGENICITY ASSAYS END POINTS

Blood stem cell Toxicoproteomics

Interleukins Assay

Chromosomal aberrations

Blood cell metabolic or functional changes and their dose response relationships

Development of micronuclei

Hematotoxicity specific Colony Forming Units (of hematopoietic precursor cells of various types)

Spreading properties of platelets

Blood stem cell Toxicogenomics

Hematotoxicity can be directly related to Biotherapeutics
OR
Indirectly due to influence on signal pathways/immune system responses

TRANS-HSC-CBCD34+
A human surrogate
In vitro model for species specific
Hematotoxicity screening



Non-clinical Hematotoxicity detected terminates development of Biotherapeutics prior to human dosing

Non-human models poorly predict species specific Hematotoxicity related adverse events

Biotherapeutics associated adverse events are 1.4 fold > than chemical pharmaceuticals

TRANS-MSC

TRANS-MSC are of Mesenchymal Phenotype
TRAN-MSC is an *invitro* human sourced progenitor/stem cell based platform model composed of undifferentiated cells with self-renewing and differentiating capabilities

Each vial contains cells with mesenchymal phenotype characterized with antibodies specific to CD73, CD90 and CD105. Each unit is negative for HIV-1, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi

Supplied as testing platform unit for predicting and measuring assay end points

- **Catalogue Number** : TR-MSC
- **Source :** Mesenchymal Phenotype

Stem cell Toxicoproteomics

Interleukins Assay

Chromosomal aberrations

Necrosis

Apoptosis

LD50

Tumor formation

Cytokines response

Stem cell distribution

Stem cell distribution

Stem cell Toxicogenomics

Stem cell differentiated lung cells toxicity

RELEVANT QUANTIFIED RESPONSES



Lung cells specific responses
Pulmonotoxicity

Transdifferentiated to

TRANS-MSC
A human surrogate
In vitro model for species specific predictive testing

The only in vitro model with differentiating capabilities



Carcinogenicity



Cultured in medium



Stem cell specific cytokines responses
Signal transduction

Biotherapeutics associated adverse events are 1.4 fold > than chemical pharmaceuticals

Products related : info@transtoxbio.com
Business related : enquiry@transtoxbio.com
Media and relations : media@transtoxbio.com
USA corporate office : (908) 325- 2508
USA Distributor Number : (844) 205- 9599
India Operations Office : +91-7799914445